撰文丨王聪 编辑丨王多鱼 排版丨水成文 基于干细胞的神经组织工程和脊髓类器官，在 脊髓损伤 （ Spinal Cord Injury， SCI） 的修复方面展现出希望。然而，天然脊髓具有细胞异质性和典型的立体结 构，这使得在类器官结构中重现其特征变得困难，因为这需要包含细胞组成、节段组织和背腹特征的组装。 2025 年 10 月 24 日，同济大学 生命科学与技术学院 朱融融 教授、同济大学附属同济医院 程黎明 教授团队合作 （ 朱颜菁 、 黄蕊奇 、 于立群 为论文共同第 一作者 ） ，在 Nature 子刊 Nature Biomedical Engineering 上发表了题为： Engineered thoracic spinal cord organoids for transplantation after spinal cord injury 的研究论文。 该研究成功构建了 具备胸段脊髓区域异质性和成熟神经回路结构的 工程化胸段脊髓类器官 （engineered thoracic spinal cord organoid，简称为 enTsOrg） ， 移植的 enTsOrg 在因完全脊髓损伤而瘫 ...

Core Insights - The article highlights a breakthrough in spinal cord injury treatment through the development of an injectable neural system biomaterial scaffold by Dr. Zhu Rongrong and her team, which offers hope to millions of patients worldwide [1][3]. Group 1: Technology Overview - The injectable biomaterial promotes nerve regeneration and induces directional axon growth, effectively creating a neural relay station to reconnect severed spinal cord pathways [3][5]. - The material has shown significant efficacy in animal trials, particularly in improving locomotion in rodents and non-human primates [6][7]. Group 2: Clinical Implications - Annually, there are approximately 80,000 to 100,000 new cases of spinal cord injuries in China, with over 3 million patients currently affected, of which 82.5% suffer from substantial spinal cord damage without effective treatment options [7][8]. - The traditional treatment methods involve surgical debridement, which often lacks suitable materials for spinal cord repair, highlighting the need for innovative solutions like the developed biomaterial [7][8]. Group 3: Research Journey - Dr. Zhu's shift to spinal cord injury research began in 2016, focusing on utilizing biomaterials for nerve regeneration, which involves a complex interplay of material design and understanding the pathological microenvironment [4][5]. - The research team faced challenges in translating efficacy from rodent models to non-human primates, with initial trials showing no improvement until a significant breakthrough was observed after four months [6][7]. Group 4: Patient Impact - The quality of life for spinal cord injury patients is severely compromised, with many unable to perform basic tasks, emphasizing the potential transformative impact of the new biomaterial if successful in clinical applications [9][10]. - The ultimate goal of the research is to enable patients to regain mobility and independence, significantly improving their overall well-being [10].